within Pharmacolibrary.Drugs.ATC.M;

model M03AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.01 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum. It is used clinically as an injectable treatment for various forms of muscle spasticity, dystonia, chronic migraine, cosmetic reduction of wrinkles, and other conditions involving overactive muscle contraction. Several serotypes exist (mainly A and B are used clinically). It is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetics model parameters available; botulinum toxin is a large protein administered locally (usually intramuscular) with minimal to no measurable systemic bioavailability. Estimates below are based on its biological properties as a protein.</p><h4>References</h4><ol><li><p>Ashkenazi, A, &amp; Blumenfeld, A (2013). OnabotulinumtoxinA for the treatment of headache. <i>Headache</i> 53 Suppl 2 54–61. DOI:<a href=&quot;https://doi.org/10.1111/head.12185&quot;>10.1111/head.12185</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24024603/&quot;>https://pubmed.ncbi.nlm.nih.gov/24024603</a></p></li><li><p>Davis, T (2020). Botulinum toxin injection, dilution confusion: The impact of toxin diffusion on clinical practice. <i>Journal of pediatric rehabilitation medicine</i> 13(2) 201–204. DOI:<a href=&quot;https://doi.org/10.3233/PRM-200721&quot;>10.3233/PRM-200721</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32568126/&quot;>https://pubmed.ncbi.nlm.nih.gov/32568126</a></p></li><li><p>Schroeder, AS, et al., &amp; Heinen, F (2006). Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. <i>Neurotoxicity research</i> 9(2-3) 189–196. DOI:<a href=&quot;https://doi.org/10.1007/BF03033938&quot;>10.1007/BF03033938</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16785117/&quot;>https://pubmed.ncbi.nlm.nih.gov/16785117</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M03AX01;
